Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07404397 · ClinicalTrials.gov registry record · Phase 2

Comparing Adjuvant Treatments for High Tone Pelvic Floor Dysfunction

A Phase 2 study of High Tone Pelvic Floor Dysfunction, sponsored by University of Michigan.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT07404397 is a Phase 2 study of High Tone Pelvic Floor Dysfunction that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07404397, a Phase 2 study of High Tone Pelvic Floor Dysfunction, is actively recruiting participants, sponsored by University of Michigan.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The researchers are comparing two treatments for high tone pelvic floor dysfunction (HTPFD) in conjunction with pelvic floor physical therapy (PFPT). The goal of this study is to find out which of two extra treatments works better for people with HTPFD when they also do regular PFPT. First, the researchers will compare a muscle relaxant medicine (cyclobenzaprine IR) to using a vibrating pelvic floor massage wand. Everyone in the study will also do pelvic floor physical therapy. The researchers want to see how these treatments affect pain, sexual health, physical ability, and overall quality of life.

Interventions

  • DRUG Cyclobenzaprine
  • DEVICE Pelvic floor massage wand
  • PROCEDURE Pelvic floor physical therapy

Study Locations (1)

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2026-02-18
Est. Completion 2026-12
Phase Phase 2

Sponsor

University of Michigan

1,327 total trials

What the Registry Record Tells You About NCT07404397

The ClinicalTrials.gov registry entry for NCT07404397 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with High Tone Pelvic Floor Dysfunction appearing as the primary indexed condition, and to 3 interventions - of which Cyclobenzaprine is the first listed.

NCT07404397 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT07404397 about?

NCT07404397 is a clinical study titled "Comparing Adjuvant Treatments for High Tone Pelvic Floor Dysfunction". The researchers are comparing two treatments for high tone pelvic floor dysfunction (HTPFD) in conjunction with pelvic floor physical therapy (PFPT). The goal of this study is to find out which of two extra treatments works better for people with HTPFD when they also do regular PFPT. First, the rese...

What is the current status of trial NCT07404397?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-02-18. Estimated completion is 2026-12.

What conditions does trial NCT07404397 study?

This clinical trial studies the following conditions: High Tone Pelvic Floor Dysfunction.

What interventions are being tested in trial NCT07404397?

The interventions under investigation include: Cyclobenzaprine (DRUG), Pelvic floor massage wand (DEVICE), Pelvic floor physical therapy (PROCEDURE).

Who is sponsoring clinical trial NCT07404397?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07404397 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.